Market Research Logo

Global Multiple Myeloma Drugs Market 2017-2021

Global Multiple Myeloma Drugs Market 2017-2021

About Multiple Myeloma Drugs

Multiple myeloma is an abnormal growth and accumulation of plasma cells in the bone marrow leading to malignancy. This can be caused by the overproduction of monoclonal immunoglobulins such as IgG, IgA, IgD, or IgE; or Bence-Jones protein. Under normal conditions, stem cells develop into B lymphocytes, mature in the lymph nodes, and are transported throughout the body. On the entry of foreign substances into the body, these B-cells develop into plasma cells and produce immunoglobulins against the disease. However, in multiple myeloma, the B-cells are damaged and give rise to many malignant plasma cells that produce excessive immunoglobulins of a single type, which the body does not require.

Technavio’s analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global multiple myeloma drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent multiple myeloma.The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Multiple Myeloma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Amgen
  • Celgene
  • Johnson & Johnson
  • Novartis
  • Takeda Pharmaceuticals
Other prominent vendors
  • AB Science
  • AbbVie
  • Acceleron Pharma
  • Acetylon Pharmaceuticals
  • Adaptimmune Therapeutics
  • Alexion Pharmaceuticals
  • AmpliMed Corporation
  • Array BioPharma
  • Benovus Bio
  • BioInvent
  • Biokine Therapeutics
  • Biotest
  • bluebird bio
  • Bristol-Meyer Squibb
  • Calithera Biosciences
  • CASI Pharmaceuticals
  • Celldex Therapeutics
  • Cellectar Biosciences
  • Chroma Therapeutics
  • Cleave Biosciences
  • Curis
  • Dicerna Pharmaceuticals
  • Eureka Therapeutics
  • F. Hoffmann-La Roche
  • Geron Corporation
  • GlycoMimetics
  • GlaxoSmithKline
  • ImmunoGen
  • Immunomedics
  • Innate Pharma
  • JW Pharmaceutical
  • Karyopharm Therapeutics
  • Kyowa Hakko Kirin
  • Merck
  • Midatech Pharma
  • Mirna Therapeutics
  • Molecular Partners
  • MorphoSys
  • NOXXON Pharma
  • Oncoceutics
  • Oncolytics Biotech
  • OncoPep
  • Oncopeptides
  • Ono Pharmaceutical
  • Otsuka Pharmaceuticals
  • Patrys
  • PharmaMar
  • Polyphor
  • Prothena Therapeutics
  • Sanofi
  • Sevion Therapeutics
  • Specialised Therapeutics
  • Spectrum Pharmaceutical
  • SymBio Pharmaceuticals
  • TaiGen Biotechnology
  • Tragara Pharmaceuticals
  • Vaxil Therapeutics
  • Vivolux
Market driver
  • Growing demand for biologic therapies
  • For a full, detailed list, view our report
Market challenge
  • Growing popularity of complementary and alternative medicines (CAM)
  • For a full, detailed list, view our report
Market trend
  • Emergence of nanomedicine platform
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Multiple Myeloma Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global multiple myeloma drugs market: Amgen, Celgene, Johnson & Johnson, Novartis, and Takeda Pharmaceuticals.

Other Prominent Vendors in the market are: AB Science, AbbVie, Acceleron Pharma, Acetylon Pharmaceuticals, Adaptimmune Therapeutics, Alexion Pharmaceuticals, AmpliMed Corporation, Array BioPharma, Benovus Bio, BioInvent, Biokine Therapeutics, Biotest, bluebird bio, Bristol-Meyer Squibb, Calithera Biosciences, CASI Pharmaceuticals, Celldex Therapeutics, Cellectar Biosciences, Chroma Therapeutics, Cleave Biosciences, Curis, Dicerna Pharmaceuticals, Eureka Therapeutics, F. Hoffmann-La Roche, Geron Corporation, GlycoMimetics, GlaxoSmithKline, ImmunoGen, Immunomedics, Innate Pharma, JW Pharmaceutical, Karyopharm Therapeutics, Kyowa Hakko Kirin, Merck, Midatech Pharma, Mirna Therapeutics, Molecular Partners, MorphoSys, NOXXON Pharma, Oncoceutics, Oncolytics Biotech, OncoPep, Oncopeptides, Ono Pharmaceutical, Otsuka Pharmaceuticals, Patrys, PharmaMar, Polyphor, Prothena Therapeutics, Sanofi, Sevion Therapeutics, Specialised Therapeutics, Spectrum Pharmaceutical, SymBio Pharmaceuticals, TaiGen Biotechnology, Tragara Pharmaceuticals, Vaxil Therapeutics, and Vivolux.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is emergence of nanomedicine platform. The market has witnessed the emergence of nanomedicine, which is likely to have a positive impact. The lipid-based nanoparticles and polymer-based approaches for the drug delivery are gaining traction in the market, owing to the limitations of current technologies. The existing technologies need numerous cells to detect the presence of a tumor.”

According to the report, one of the major drivers for this market is growing demand for biologic therapies. The market has been witnessing a growing demand for biologic therapies, which is expected to drive market growth. Biologic therapy is a treatment that triggers the body's immune system to fight myeloma cells. Biologic therapies boost the immune system cells that identify and attack cancer cells. The demand for targeted therapies is due to its higher efficacy than other conventional therapies, which involves in destroying healthy cells too.

Further, the report states that the growing popularity of CAM is expected to hinder growth prospects in the market. With the increasing side effects of conventional drugs, the individuals are seeking CAM therapies. The increased demand for these therapies is also due to the high cost of multiple myeloma therapeutics.

Companies Mentioned

Amgen, Celgene, Johnson & Johnson, Novartis, Takeda Pharmaceuticals, AB Science, AbbVie, Acceleron Pharma, Acetylon Pharmaceuticals, Adaptimmune Therapeutics, Alexion Pharmaceuticals, AmpliMed Corporation, Array BioPharma, Benovus Bio, BioInvent, Biokine Therapeutics, Biotest, bluebird bio, Bristol-Meyer Squibb, Calithera Biosciences, CASI Pharmaceuticals, Celldex Therapeutics, Cellectar Biosciences, Chroma Therapeutics, Cleave Biosciences, Curis, Dicerna Pharmaceuticals, Eureka Therapeutics, F. Hoffmann-La Roche, Geron Corporation, GlycoMimetics, GlaxoSmithKline, ImmunoGen, Immunomedics, Innate Pharma, JW Pharmaceutical, Karyopharm Therapeutics, Kyowa Hakko Kirin, Merck, Midatech Pharma, Mirna Therapeutics, Molecular Partners, MorphoSys, NOXXON Pharma, Oncoceutics, Oncolytics Biotech, OncoPep, Oncopeptides, Ono Pharmaceutical, Otsuka Pharmaceuticals, Patrys, PharmaMar, Polyphor, Prothena Therapeutics, Sanofi, Sevion Therapeutics, Specialised Therapeutics, Spectrum Pharmaceutical, SymBio Pharmaceuticals, TaiGen Biotechnology, Tragara Pharmaceuticals, Vaxil Therapeutics, and Vivolux.

  • Executive summary
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key customer segments of global multiple myeloma drugs market
      • Table Factors affecting the adoption rates of multiple myeloma drugs market
  • Disease overview
    • Understanding the disease
  • Pipeline analysis
    • Table Pipeline landscape
    • Table Pipeline analysis
  • Market landscape
    • Global multiple myeloma drugs market
      • Table Global multiple myeloma drugs market snapshot
      • Table Global multiple myeloma drugs market 2016-2021 ($ billions)
      • Table Opportunity analysis of global multiple myeloma drugs market
      • Table Opportunity analysis in developed and emerging markets
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by therapy
    • Table Segmentation of global multiple myeloma drugs market by therapy 2016
    • Table Lifecycle analysis of segments in global multiple myeloma drugs market 2016
    • Targeted therapy
    • Biologic therapy
    • Chemotherapy
    • Others
  • Geographical segmentation
    • Table Segmentation of global multiple myeloma drugs market based on geography 2016 and 2021
    • Table Multiple myeloma drugs market revenue by geography 2016-2021 ($ billions)
    • Multiple myeloma drugs market in Americas
      • Table Market scenario in Americas
      • Table Multiple myeloma drugs market in Americas 2016-2021 ($ billions)
    • Multiple myeloma drugs market in EMEA
      • Table Market scenario in EMEA
      • Table Multiple myeloma drugs market in EMEA 2016-2021 ($ billions)
    • Multiple myeloma drugs market in APAC
      • Table Market scenario in APAC
      • Table Multiple myeloma drugs market in APAC 2016-2021 ($ billions)
      • Table Key drivers and challenges in APAC
  • Market drivers
    • Growing demand for biologic therapies
    • Paradigm shift toward the adoption of novel proteasome inhibitors
    • Presence of large patient pool
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Growing popularity of complementary and alternative medicines (CAM)
      • Table Alternative therapies for multiple myeloma drugs
    • High costs affecting the adoption rates of multiple myeloma drugs
    • Adverse effects of drugs
      • Table Forcefield analysis of drivers and challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Emergence of nanomedicine platform
      • Table Key factors driving the adoption of nanomedicine
    • Advent of microRNA therapeutics
      • Table Factors driving the adoption of miRNA therapeutics
    • Increasing inorganic growth strategies
      • Table Key deals in global multiple myeloma drugs market
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global multiple myeloma drugs market 2015
      • Table Market share analysis in global multiple myeloma drugs market
      • Table Competitive analysis of global multiple myeloma drugs market
      • Table Market penetration of various multiple myeloma drugs manufacturers worldwide (2016)
  • Key vendor analysis
    • Amgen
      • Table Amgen: Key highlights
      • Table Amgen: Strength assessment
      • Table Amgen: Strategy assessment
      • Table Amgen: Opportunity assessment
    • Celgene
      • Table Celgene: Key highlights
      • Table Celgene: Strength assessment
      • Table Celgene: Strategy assessment
      • Table Celgene: Opportunity assessment
      • Table Celgene: YoY revenue and growth rate of REVLIMID 2013-2015 ($ billions)
      • Table Celgene: YoY revenue and growth rate of POMALYST 2013-2015 ($ millions)
      • Table Celgene: YoY revenue and growth rate of THALOMID 2013-2015 ($ millions)
    • Johnson & Johnson
      • Table Johnson & Johnson: Key highlights
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
      • Table Johnson & Johnson: YoY global revenue comparison of VELCADE 2013-2015 ($ billions)
    • Novartis
      • Table Novartis: Key highlights
      • Table Novartis: Strength assessment
      • Table Novartis: Strategy assessment
      • Table Novartis: Opportunity assessment
    • Takeda Pharmaceuticals
      • Table Takeda Pharmaceuticals: Key highlights
      • Table Takeda Pharmaceuticals: Strength assessment
      • Table Takeda Pharmaceuticals: Strategy assessment
      • Table Takeda Pharmaceuticals: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report